Paid Clinical Trials Tennessee
Discover 1,819 paid clinical trials in Tennessee. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies
Sponsor:
Ellipses Pharma
Location:
Code:
NCT05443126
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
EP0031
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT05287126
Conditions
Ulcerative Colitis
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Etrasimod
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Sponsor:
Boston Children's Hospital
Location:
Code:
NCT05600426
Conditions
Severe Aplastic Anemia
Eligibility Criteria
Sex: All
Age: 0 - 25
Healthy Volunteers: Not accepted
Interventions
cyclosporine
Matched Unrelated Donor Hematopoetic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Methotrexate
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerPhase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Sponsor:
Ellipses Pharma
Location:
Code:
NCT05573126
Conditions
Hormone Receptor-positive Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Vosilasarm
Elacestrant
Everolimus
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Sponsor:
Krystal Biotech, Inc.
Location:
Code:
NCT06228326
Conditions
Lung Cancer, Non-small Cell
Lung Cancer Metastatic
Solid Tumor, Adult
Advanced Cancer
Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KB707
Pembrolizumab (KEYTRUDA®)
Chemotherapy
Life's End Benefits of CannaBidiol and TetrahYdrocannabinolLife's End Benefits of CannaBidiol and TetrahYdrocannabinol
Sponsor:
University of Southern California
Location:
Code:
NCT05644262
Conditions
Agitation
Dementia
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
T2:C100
Placebo
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Sponsor:
Immunovant Sciences GmbH
Location:
Code:
NCT06754462
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IMVT-1402
Placebo
Low-Dose Ketamine Infusion During Burn Wound CareLow-Dose Ketamine Infusion During Burn Wound Care
Sponsor:
University of Tennessee
Location:
Code:
NCT06506565
Conditions
Burn
Pain
Dissociation
Opioid
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ketamine
0.9% NaCl
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington DiseaseImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Sponsor:
Vanderbilt University Medical Center
Location:
Code:
NCT04713982
Conditions
Huntington Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Deutetrabenazine
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Sponsor:
Cytokinetics
Location:
Code:
NCT06736574
Conditions
Heart Failure
Heart Failure With Reduced Ejection Fraction
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Omecamtiv Mecarbil (OM)
Placebo